Tổng hợp một số dẫn chất 6-(n-butylamino)-2-arylquinazolin-4(3H)-on hướng kháng ung thư

Abstract

A senes of 2-arylquinazolin-4(3H)-on was designed in expectaion of anticancer effects. Substitutions at C6 and C2' position < >f ¡he structures were introduced. Targeted compound 6a-d were obtained by a 3-steps pathway from 2-amlno-5-butylannnobenzamid and corresponding aldehydes. Cytotoxicity of the synthesized compounds were tested against two cancer cell lines (human epidermic carcinoma-KB and hepatocellular carcinoma-HepG2). As expected, all the tested compounds exhibited stronger cytotoxicity than ellipticine. Notably, compound 6c and 6d exposed the desirable activity 18 -21 times as strong as ellipticine with IC50 ranging at 0,09-0,12 uM. These findings clarified why the 2-arylquinazolin-4(3H)-on derivatives with 2’-substitution have been considered as very potential anticancer agents.